Merck
CN
  • Ultrastructural changes associated with dexamethasone-induced ocular hypertension in mice.

Ultrastructural changes associated with dexamethasone-induced ocular hypertension in mice.

Investigative ophthalmology & visual science (2014-07-17)
Darryl R Overby, Jacques Bertrand, Ozan-Yüksel Tektas, Alexandra Boussommier-Calleja, Martin Schicht, C Ross Ethier, David F Woodward, W Daniel Stamer, Elke Lütjen-Drecoll
摘要

To determine whether dexamethasone (DEX)-induced ocular hypertension (OHT) in mice mimics the hallmarks of steroid-induced glaucoma (SIG) in humans, including reduced conventional outflow facility (C), increased extracellular matrix (ECM), and myofibroblasts within the outflow pathway. Osmotic mini-pumps were implanted subcutaneously into C57BL/6J mice for systemic delivery of DEX (3-4 mg/kg/d, n = 31 mice) or vehicle (n = 28). IOP was measured weekly by rebound tonometry. After 3 to 4 weeks, mice were euthanized and eyes enucleated for ex vivo perfusion to measure C, for electron microscopy to examine the trabecular meshwork (TM) and Schlemm's canal (SC), or for immunohistochemistry to examine type IV collagen and α-smooth muscle actin. The length of basement membrane material (BMM) was measured along the anterior-posterior extent of SC by electron microscopy. Ultrastructural changes in BMM of DEX-treated mice were compared against archived human SIG specimens. Dexamethasone increased IOP by 2.6 ± 1.6 mm Hg (mean ± SD) over 3 to 4 weeks and decreased C by 52% ± 17% versus controls. Intraocular pressure elevation correlated with decreased C. Dexamethasone treatment led to increased fibrillar material in the TM, plaque-like sheath material surrounding elastic fibers, and myofibroblasts along SC outer wall. The length of BMM underlying SC was significantly increased in mice with DEX and in humans with SIG, and in mice decreased C correlated with increased BMM. Dexamethasone-induced OHT in mice mimics hallmarks of human SIG within 4 weeks of DEX treatment. The correlation between reduced C and newly formed ECM motivates further study using DEX-treated mice to investigate the pathogenesis of conventional outflow obstruction in glaucoma.

材料
货号
品牌
产品描述

Sigma-Aldrich
甘油, for molecular biology, ≥99.0%
Sigma-Aldrich
甘油, ACS reagent, ≥99.5%
Sigma-Aldrich
甘油, ≥99.5%
Sigma-Aldrich
甘油, ReagentPlus®, ≥99.0% (GC)
Supelco
甘油, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
甘油, BioXtra, ≥99% (GC)
Sigma-Aldrich
甘油, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for electrophoresis, ≥99% (GC)
Sigma-Aldrich
甘油 溶液, 83.5-89.5% (T)
Sigma-Aldrich
甘油, meets USP testing specifications
USP
甘油, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
甘油, FCC, FG
Sigma-Aldrich
甘油, puriss., anhydrous, 99.0-101.0% (alkalimetric)
Sigma-Aldrich
甘油, BioUltra, for molecular biology, anhydrous, ≥99.5% (GC)
Sigma-Aldrich
甘油 溶液, puriss., meets analytical specification of Ph. Eur., BP, 84-88%
Sigma-Aldrich
甘油, puriss. p.a., ACS reagent, anhydrous, dist., ≥99.5% (GC)
Supelco
甘油, analytical standard
Sigma-Aldrich
恩诺沙星, ≥99.0%
Supelco
恩诺沙星, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
甘油, tested according to Ph. Eur., anhydrous
Supelco
恩诺沙星, VETRANAL®, analytical standard
Supelco
卡洛芬, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
卡洛芬, VETRANAL®, analytical standard
USP
恩诺沙星, United States Pharmacopeia (USP) Reference Standard
恩诺沙星, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
甘油, Vetec, reagent grade, 99%
卡洛芬, European Pharmacopoeia (EP) Reference Standard
恩诺沙星, European Pharmacopoeia (EP) Reference Standard
卡洛芬, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
甘油, Vetec, reagent grade